# Sotera Health Company (SHC) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $18.90, market value $5.4 billion.

## Valuation
- **P/E (trailing): 33.2×** (5-yr avg 75.5×, 3-yr avg 81.5×). Sotera Health Company trades at 33.2× trailing earnings, well below its own five-year average of 75.5×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 17.6×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.26**. A PEG of 0.26 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 4.4×**. Each dollar of revenue is priced at 4.4×.
- **Price / book: 8.1×**. The shares trade at 8.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 2.1%** (5-yr avg 0.7%). Free cash flow equals 2.1% of the market value, above its five-year average of 0.7%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 3.0%**. The inverse of the P/E: 3.0% of the price is earned each year.

## Profitability
- **Gross margin: 55.0%**. Sotera Health Company keeps 55.0% of revenue after the direct cost of what it sells.
- **Net margin: 6.7%**. 6.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 12.9%**. 12.9% on shareholders' equity is solid.
- **Return on assets: 5.0%**. Each dollar of assets produces 5.0% of profit.

## Growth
- **Revenue growth (1 yr): 5.7%** (3-yr 5.1%/yr, 5-yr 7.3%/yr). Revenue grew 5.7% over the last year, against 7.3% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 68.8%**. Earnings per share rose 68.8%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 16.0%/yr**. Free cash flow has compounded at 16.0% a year over three years.

## Financial health
- **Debt to equity: 3.53**. Debt is 3.53 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Sotera Health Company does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (9 analysts). 9 analysts cover Sotera Health Company; the consensus is buy, with an average price target of $22.72 (+20% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 21.9%** (YTD 7.1%, 3-mo 21.0%). The shares are up 21.9% over twelve months including dividends.
- **From 52-week high: -4.8%** (44.4% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 1.15** (volatility 29%). Beta of 1.15 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SHC · Page: https://foliofundamentals.com/stocks/shc

Not investment advice.